What's new?

Sofinnova Partners Announces Sale of Corvidia Therapeutics to Novo Nordisk

Novo Nordisk acquires Corvidia for $2.1B with an upfront payment of $725M in cash   Sofinnova Partners co-founded Corvidia as its sole seed financial investor in 2015 with serial entrepreneur Michael Davidson   PARIS, France – June 11, 2020 - Sofinnova Partners, a leading European life sciences venture capital firm...

Shockwave Medical Announces That CMS Has Created New Codes for Intravascular Lithotripsy

Centers for Medicare & Medicaid Services Issues New Codes for Peripheral Intravascular Lithotripsy Performed in Hospital Outpatient and Inpatient Settings SANTA CLARA, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascula...

Calliditas Therapeutics Prices its Initial Public Offering on The Nasdaq Global Select Market in the United States

STOCKHOLM, June 5, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") announced today the pricing of its initial public offering on The Nasdaq Global Select Market by way of a capital increase of 9,230,770 new common shares, consisting of a public offering of 8,306,770 common shares in the form o...

NodThera Announces Close of $55 Million Series B Financing

Financing round led by Novo Ventures and includes new investors Cowen Healthcare Investments and Sanofi Ventures, as well as existing investors 5AM Ventures, F-Prime Capital, Sofinnova Partners and founding investor Epidarex Capital   Proceeds to support advancement of pipeline of small molecule NLRP3 inflammasome ...

RGENIX Shows Clinical Activity of Novel Agent RGX-202 in Patients with KRAS Mutant Colorectal Cancer in Phase 1 Trial

Data from Phase 1 Trial of RGX-202 Presented at 2020 ASCO Virtual Scientific Program   May 29, 2020 08:02 AM Eastern Daylight Time   NEW YORK--(BUSINESS WIRE)--RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is pr...

RefleXion Announces Clinical Collaboration to Evaluate Biology-guided Radiotherapy with Merck’s KEYTRUDA® for Certain Late-Stage Cancers

HAYWARD, Calif., May 28, 2020 – RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) for treating all stages of cancer, today announced a clinical collaboration with Merck (known as MSD outside the U.S. and Canada) to evaluate the safety and efficacy of KEYTRUDA® (pembrol...

Biotalys awarded €1.6 million VLAIO research grant

Funding will enable accelerated development of a proprietary platform for the industrial production of Biotalys’ protein-based biocontrols   GHENT, Belgium, May 26, 2020 (GLOBE NEWSWIRE) -- Biotalys NV, a transformative food and crop protection company, today announced that it has been rewarded a €1.6 million resea...

Abivax Announces German Regulatory Approval of ABX464 Covid-19 Phase 2b/3 COVID-19 Clinical Trial

Second regulator to approve "miR-AGE" Phase 2b/3 trial after clearance of French authorities (ANSM)   1,034-patient placebo-controlled trial to test oral ABX464's triple effect in COVID-19 patients: antiviral, anti-inflammatory and tissue repair Bpifrance provided €36 million non-dilutive funding for ABX464 COVID-1...

Comet Bio Announces Positive Clinical Trial Results for its Prebiotic Arrabina™

Arrabina™ Arabinoxylan GI tolerance no different than placebo   SCHAUMBURG, Ill., May 20, 2020 /PRNewswire/ -- Comet Bio announced today the successful completion of its randomized, placebo-controlled, crossover clinical trial evaluating the gastrointestinal (GI) tolerability and prebiotic effects of its Arabinoxyl...

HotSpot Therapeutics Completes $65 Million Series B Financing to Advance Pipeline of Novel Allosteric Medicines

Financing Accelerates Development of First-in-Class Therapies with Genetically Validated Mechanisms for Treatment of Autoimmune Diseases, Rare Diseases and Cancer   BOSTON, May 21, 2020 /PRNewswire/ -- HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery and development of first-in-class allo...

Abivax Receives ANSM and Ethics Committee Clearance to Test its Development Candidate ABX464 in 1,034 COVID-19 Patients in Randomized Phase 2B/3 Clinical Trial

French regulator, ANSM, as well as Ethics Committee, CPP, have cleared ABX464 for Phase 2b/3 “ miR-AGE ” testing

1 2 3 4 5